EGCG slows post-traumatic OA Progression: in vivo evidence and a novel mechanism underlying the downregulation of ADAMTS5

s / Osteoarthritis and Cartilage 22 (2014) S57–S489 S322 Wilcoxon test was used within groups and the Man-Whitney test when comparing groups. Significance level was a p-value of <0.05. All data given are on the basis of the intention to treat (ITT). To test for a possible dose-dependency the bodyweight of each patient was plotted against the different symptom scores, and a correlation test was made on each of the two groups at the initial level and after 6 and 12 weeks of treatment. Results: The two groups were comparable at the initial level regarding age, sex, bodyweight, consumption of rescue medication and the severity of OA. Twelveweeks of active treatment resulted in a reduction inWOMAC pain from 17.79 þ/8.80 to 16.57þ/-9.88, p<0.14, whilst the placebo group showed a decline in pain score from 17.96þ/-7.08 to 14.41 þ/-7.60, p<0.001. Comparing groups yielded a Man-Whitney pvalue of 0.058. No correlation was present between weight and pain score in either of the two groups on the day of inclusion. After both 6 and 12 weeks of active treatment, there was a significant negative correlation between weight and pain score (p<0.021 and p<0.022, respectively). The lower the weight the more pronounced the reduction in pain. No correlation was observed at any time point during placebo. The ADL score declined from 60.59 þ/-31.33 to 53.91 þ/30.59 after 12 weeks of active treatment (p<0.016). Placebo resulted in a decline from 55.71 þ/-25.19 to 43.90 (p<0.001). Comparing groups yielded a ManWhitney p-value of 0.098. There was no correlation between weight and ADL score in either of the two groups on the day of inclusion. Six and 12 weeks of active treatment, however, resulted in a negative correlation between weight and ADL score (p<0.019 and p<0.009 respectively). To summarize, the less the weight of the patient the better the impact from treatment. In the placebo group there was no significant correlation betweenweight and ADL score at any time point. Similar results for active treatment and placebo were obtained when testing the secondary effect variable. CRP significantly declined as a result of active treatment. Man-Whitney p-value 0.042. Conclusions: The present data suggest that patients with osteoarthritis of the knee or hip can benefit from treatment with the present rose-hip powder, when given a booster of 5 grams daily for 3 weeks, followed by 2.5 g for the following 9 weeks, with the effect becoming statistically significant in the group of patients of lower weight than 84 kg. This lowdose also significantly reduces CRP. 561 EGCG SLOWS POST-TRAUMATIC OA PROGRESSION: IN VIVO EVIDENCE AND A NOVEL MECHANISM UNDERLYING THE DOWNREGULATION OF ADAMTS5 D.J. Leong y, Z. He y, D.M. Hirsh y, S.J. Kim y, K.E. Sperling y, R.J. Majeska z, M.B. Schaffler z, J.A. Hardin y, N.J. Cobelli y, H.B. Sun y. yAlbert Einstein Coll. of Med., Bronx, NY, USA; z The City Coll. of NY, New